GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?
Emir Muzurović, Volkan Yumuk, Manfredi Rizzo
Topics & Concepts
MedicineOverweightDiabetes mellitusAtherosclerotic cardiovascular diseaseDiseaseObesityGlucagon-like peptide 1 receptorType 2 diabetesDual (grammatical number)Internal medicineEndocrinologyReceptorAgonistArtLiteratureDiabetes Treatment and ManagementPharmacology and Obesity TreatmentDiet and metabolism studies